Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Non-Current Assets (2016 - 2025)

Kiora Pharmaceuticals' Non-Current Assets history spans 11 years, with the latest figure at $2.5 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 63.05% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $23.8 million, down 24.64%, while the annual FY2025 figure was $2.5 million, 63.05% down from the prior year.
  • Non-Current Assets reached $2.5 million in Q4 2025 per KPRX's latest filing, down from $7.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $13.8 million in Q2 2021 to a low of $2.5 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $9.5 million, with a median of $9.0 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: skyrocketed 139.74% in 2021, then crashed 63.05% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $11.1 million in 2021, then fell by 0.91% to $11.0 million in 2022, then dropped by 18.7% to $9.0 million in 2023, then dropped by 24.46% to $6.8 million in 2024, then plummeted by 63.05% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Non-Current Assets are $2.5 million (Q4 2025), $7.2 million (Q3 2025), and $7.2 million (Q2 2025).